-
公开(公告)号:US08178570B2
公开(公告)日:2012-05-15
申请号:US10552424
申请日:2004-04-08
申请人: Jeff Chen , Lisa Esther Dalrymple , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , James William Leahy , Brian Hugh Ridgway , Grace Mann , Larry W. Mann , Craig Stacy Takeuchi , Joan C. Sangalang
发明人: Jeff Chen , Lisa Esther Dalrymple , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , James William Leahy , Brian Hugh Ridgway , Grace Mann , Larry W. Mann , Craig Stacy Takeuchi , Joan C. Sangalang
IPC分类号: A01N43/64 , A01N43/54 , A61K31/41 , C07D239/42 , C07D401/04 , C07D249/08
CPC分类号: C07D401/04 , A61K31/4439 , A61K31/506
摘要: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
摘要翻译: 本发明提供调节蛋白激酶酶活性以调节细胞活性如增殖,分化,程序性细胞死亡,迁移和化学侵蚀的化合物。 本发明的化合物抑制,调节和/或调节激酶,特别是Tie-2。 使用化合物及其药物组合物治疗激酶依赖性疾病和病症的方法也是本发明的一个方面。
-
公开(公告)号:US08222263B2
公开(公告)日:2012-07-17
申请号:US12049225
申请日:2008-03-14
申请人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
发明人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
IPC分类号: A61K31/517 , A01N43/54
CPC分类号: C07D239/42 , C07D239/70 , C07D239/84 , C07D239/95 , C07D401/04 , C07D403/12
摘要: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.
摘要翻译: 本发明涉及式I化合物或其单一异构体; 其中除了制备式I化合物的方法之外,化合物任选为其药学上可接受的盐,水合物,溶剂合物或其组合,以及使用式I化合物治疗癌症的方法。
-
公开(公告)号:US20120238570A1
公开(公告)日:2012-09-20
申请号:US13487559
申请日:2012-06-04
申请人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
发明人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
IPC分类号: A61K31/517 , A61K31/519 , C07D413/04 , A61P35/00 , C07D239/84 , C07D471/04 , C07D403/12 , A61K31/5377 , C07D239/70
CPC分类号: C07D239/42 , C07D239/70 , C07D239/84 , C07D239/95 , C07D401/04 , C07D403/12
摘要: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.
摘要翻译: 本发明涉及式I化合物或其单一异构体; 其中除了制备式I化合物的方法之外,化合物任选为其药学上可接受的盐,水合物,溶剂合物或其组合,以及使用式I化合物治疗癌症的方法。
-
公开(公告)号:US08754092B2
公开(公告)日:2014-06-17
申请号:US13487594
申请日:2012-06-04
申请人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
发明人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
IPC分类号: A01N43/54 , A61K31/517 , C07D239/72 , C07D401/00
CPC分类号: C07D239/42 , C07D239/70 , C07D239/84 , C07D239/95 , C07D401/04 , C07D403/12
摘要: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.
-
公开(公告)号:US20090105211A1
公开(公告)日:2009-04-23
申请号:US12049225
申请日:2008-03-14
申请人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
发明人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
IPC分类号: C07D239/84 , C07D413/12 , A61K31/517 , A61K31/5377 , A61K31/496 , A61K31/553 , A61K31/55 , C07D401/12 , C07D403/12 , A61P35/00 , C07D401/14
CPC分类号: C07D239/42 , C07D239/70 , C07D239/84 , C07D239/95 , C07D401/04 , C07D403/12
摘要: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.
摘要翻译: 本发明涉及式I化合物或其单一异构体; 其中除了制备式I化合物的方法之外,化合物任选为其药学上可接受的盐,水合物,溶剂合物或其组合,以及使用式I化合物治疗癌症的方法。
-
公开(公告)号:US08796294B2
公开(公告)日:2014-08-05
申请号:US13487559
申请日:2012-06-04
申请人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
发明人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
IPC分类号: A01N43/54 , A61K31/517 , C07D239/72 , C07D401/00
CPC分类号: C07D239/42 , C07D239/70 , C07D239/84 , C07D239/95 , C07D401/04 , C07D403/12
摘要: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.
摘要翻译: 本发明涉及式I化合物或其单一异构体; 其中除了制备式I化合物的方法之外,化合物任选为其药学上可接受的盐,水合物,溶剂合物或其组合,以及使用式I化合物治疗癌症的方法。
-
公开(公告)号:US20120245139A1
公开(公告)日:2012-09-27
申请号:US13487594
申请日:2012-06-04
申请人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
发明人: Suleyman Bahceci , William Bajjalieh , Jeff Chen , Sergey Epshteyn , Timothy Patrick Forsyth , Tai Phat Huynh , Byung Gyu Kim , James W. Leahy , Matthew Sangyup Lee , Gary L. Lewis , Morrison B. Mac , Grace Mann , Charles K. Marlowe , Brian Hugh Ridgway , Joan C. Sangalang , Xian Shi , Craig Stacy Takeuchi , Yong Wang
IPC分类号: A61K31/517 , A61P35/00 , A61K31/55 , A61K31/519 , A61K31/5377 , A61K31/553
CPC分类号: C07D239/42 , C07D239/70 , C07D239/84 , C07D239/95 , C07D401/04 , C07D403/12
摘要: The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.
-
公开(公告)号:US08013156B2
公开(公告)日:2011-09-06
申请号:US10549300
申请日:2004-03-19
申请人: Lynne Canne Bannen , S. David Brown , Wei Cheng , Vasu Jammalamadaka , John M. Nuss , Morrison B. Mac , Jason Jevious Parks , Matthew A. Williams , Wei Xu , Atwood Kim Cheung , Lisa Esther Dalrymple , Sergey Epshteyn , Mohamed Abdulkader Ibrahim , James William Leahy , Gary Lee Lewis , Robin Tammie Noguchi , Larry Wayne Mann , Brian Hugh Ridgway , Joan C. Sangalang , Kevin Luke Schnepp , Xian Shi , Richard George Khoury
发明人: Lynne Canne Bannen , S. David Brown , Wei Cheng , Vasu Jammalamadaka , John M. Nuss , Morrison B. Mac , Jason Jevious Parks , Matthew A. Williams , Wei Xu , Atwood Kim Cheung , Lisa Esther Dalrymple , Sergey Epshteyn , Mohamed Abdulkader Ibrahim , James William Leahy , Gary Lee Lewis , Robin Tammie Noguchi , Larry Wayne Mann , Brian Hugh Ridgway , Joan C. Sangalang , Kevin Luke Schnepp , Xian Shi , Richard George Khoury
IPC分类号: C07D401/14 , C07D403/14 , A61K31/4425 , A61K31/495 , A61K31/506 , A61P19/02 , A61P35/00
CPC分类号: A61K31/496 , C07D213/75 , C07D239/42 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12 , C07D417/14
摘要: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
摘要翻译: 本发明提供调节蛋白激酶酶活性以调节细胞活性如增殖,分化,程序性细胞死亡,迁移和化学侵蚀的化合物。 本发明的化合物抑制,调节和/或调节激酶,特别是Tie-2。 使用化合物及其药物组合物治疗激酶依赖性疾病和病症的方法也是本发明的一个方面。
-
公开(公告)号:US20090186905A1
公开(公告)日:2009-07-23
申请号:US10598911
申请日:2005-03-31
IPC分类号: A61K31/426 , A61K31/496 , A61K31/4725 , A61K31/4439 , C07D413/06 , C07D417/06 , C07D277/30 , A61P35/00
CPC分类号: C07D277/56 , C07D225/06 , C07D233/90 , C07D261/10 , C07D263/34 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12
摘要: The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R1, R2, R3 and R4 are defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more specifically ALK kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions; (Formula I).
摘要翻译: 本发明涉及式I化合物,其中L,X,Y,Z,R 1,R 2,R 3和R 4在本文中定义。 本发明还提供了使用化合物抑制激酶,更具体地说是ALK激酶的方法。 本发明提供用于调节蛋白激酶酶活性以调节细胞活性如增殖,分化,程序性细胞死亡,迁移和化学侵蚀的化合物。 本发明的化合物抑制,调节和/或调节与上述细胞活性变化相关的激酶受体信号转导途径,本发明包括含有这些化合物的组合物,以及使用它们治疗激酶依赖性疾病和病症的方法 ; (式I)。
-
公开(公告)号:US07973061B2
公开(公告)日:2011-07-05
申请号:US10598911
申请日:2005-03-31
IPC分类号: A61K31/41 , A61K31/415 , C07D249/00 , C07D257/04
CPC分类号: C07D277/56 , C07D225/06 , C07D233/90 , C07D261/10 , C07D263/34 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12
摘要: The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R1, R2, R3 and R4 are defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more specifically ALK kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions; (Formula I).
摘要翻译: 本发明涉及式I化合物,其中L,X,Y,Z,R 1,R 2,R 3和R 4在本文中定义。 本发明还提供了使用化合物抑制激酶,更具体地说是ALK激酶的方法。 本发明提供用于调节蛋白激酶酶活性以调节细胞活性如增殖,分化,程序性细胞死亡,迁移和化学侵蚀的化合物。 本发明的化合物抑制,调节和/或调节与上述细胞活性变化相关的激酶受体信号转导途径,本发明包括含有这些化合物的组合物,及其用于治疗激酶依赖性疾病和病症的方法 ; (式I)。
-
-
-
-
-
-
-
-
-